Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas

Inclusion Criteria:

* Angiosarcoma histologically proven
* Metastatic or locally advanced and not accessible to surgery treatment
* Measurable tumor with at least 1 measurable lesion, according to RECIST
* For angiosarcoma in irradiated region, absence of clinical arguments of progression of the tumor prior treated by radiation
* At least 28 days since the previous treatment (systemic or major surgery)
* Performance Status (ECOG) ≤ 1
* Man or woman \>= 18 years
* Polynuclear neutrophils \>1500/mm3, platelets \> 100 000/ mm3, Hemoglobin \> 9.0 g/dl
* Total bilirubin ≤ 1.5 x USL, AST and ALT ≤ 2.5 x USL (or ≤ 5 if hepatic metastasis )
* Serum creatinin ≤ 1.5 x USL or clearance calculated \> 50 ml/mn (Cockcroft formulae)
* Absence of hematuria on dipstick
* Proteinuria on dipstick \<2+, if \>2, the 24 hours proteinuria must be \< 1g
* Albumin \> 35 g/l and lymphocytes \> 700/mm3 attesting a life expectancy \> 3 months
* Normal cardiac function : LVEF ≥ 50%
* Normal coagulation test : INR ≤ 1.5 and TCA ≤ 1.5 x USL within 7 days before inclusion
* Systolic BP ≤ 150 mmHg and diastolic BP ≤ 100 mmHg
* Negative pregnancy test for women of reproductive potential(within 7 days before treatment start)
* Effective contraceptive methods for male and female (if applicable) during the period of treatment and until the 6 months after the last administration of Bevacizumab
* Adequate central veinous access
* Patient covered by government health insurance
* Informed consent form signed by the patient

Exclusion Criteria:

* Patients that have received more than 2 regimens of chemotherapy whatever the indication
* Kaposi's sarcoma, hemangio-endothelioma, hemangio-pericytoma (Malignant solitary fibrous tumor)
* Surgery (except the diagnostic biopsy) or radiotherapy within the past 4 weeks before inclusion, except antalgic radiotherapy
* Uncontrolled, active peptic ulcer,
* Other malignant evolutive tumor
* Previous thrombotic or hemorrhagic disorders
* Clinically significant cardiovascular disease (stroke within 6 months prior inclusion, unstable angina, heart failure, myocardial infarction, arrhythmia requiring treatment)
* Anticoagulant treatment for curative aim within 10 days before beginning of treatment (oral or parenteral administration), aspirin \> 325 mg/day, or Plavix or a thrombolytic (thrombolytics for preventive use is permitted) or anti-platelet (dipyridamol, ticlopidine, clodiprogel, cilostazol)
* Chronic treatment(more than 15 days) by every AINS including aspirin \> 325 mg/j
* Currently active bacterial or fungus infection (grade \> 2 CTCAE v4.02)
* Known HIV1, HIV2, hepatitis B or hepatitis C infections
* Presence of known meningeal or brain metastasis
* Epilepsy requiring the use of anti-epileptic
* Previous organ transplant
* Peripheral stem cell transplantation within 4 months prior to inclusion in the study
* Using of drugs affecting the biological response, for example G-CSF, within the 3 weeks before inclusion
* Kidney dialysis patient
* Clinically significant neuropathy (grade\> 2 CTCAE V4.02)
* Any circumstance that could jeopardise compliance or proper follow-up during the trial
* Pregnant or nursing women. Women should not breastfeed for at least 6 months after the last administration of Bevacizumab
* Constitutional or acquired coagulopathy
* Uncontrolled hypertension (SBP\> 150 mmHg or DBP\> 100 mmHg)
* Known hypersensitivity to paclitaxel or to one of its excipients (Cremophor EL, to Bevacizumab components, to products of Chinese hamster ovary cells (CHO) or other recombinant human or humanized antibodies
* Patients unable to undergo trail medical follow-up for geographical, social or psychological reasons
* Patient refusal of ambulatory care